Disc Medicine, Inc. (NASDAQ: IRON) has presented positive additional clinical data for its portfolio at the European Hematology Association (EHA) 2024 Congress. The company shared updated analyses from the Aurora and Beacon studies, demonstrating the clinical activity of Bitopertin in Erythropoietic Protoporphyria (EPP) and supporting the drug's development path forward.
The data from the Aurora study, a randomized, double-blind, placebo-controlled phase 2 clinical trial, showed significant reductions in protoporphyrin IX (PPIX) and meaningful improvements in light tolerance in subjects receiving Bitopertin, with dose-dependent reductions in phototoxic reactions and improvements in patient global impression of change (PGIC). The study also demonstrated that Bitopertin was generally well-tolerated with no reported serious adverse events (SAEs) to date.
Moreover, data from the ongoing Phase 1b trial of Disc-0974 in myelofibrosis (MF) patients revealed greater than 60% hematologic response rates, with durable increases in hemoglobin levels and reductions in transfusion burden. The Phase 1 trial of Disc-3405 in healthy volunteers also demonstrated sustained, meaningful induction of hepcidin and over 50% suppression of mean serum iron, with the drug being generally well-tolerated.
In the Phase 1b/2a multi-center, open-label, ascending-dose clinical trial of Disc-0974 in MF patients, substantial and sustained reductions in hepcidin levels and increases in iron were observed in patients for several weeks after each dose. The trial also showed strong hematologic responses across all patient types, with a majority of patients demonstrating a significant hemoglobin response sustained for at least 12 weeks.
From the initial data presented from the Phase 1 clinical trial of Disc-3405 in healthy volunteers, it was evident that the drug led to a meaningful dose-dependent increase in hepcidin and corresponding reduction in serum iron across all dose levels, with a mean serum iron reduction in excess of 50% from baseline achieved in the 150* and 300-mg dose groups.
Today the company's shares have moved 19.1% to a price of $46.66. For the full picture, make sure to review Disc Medicine's 8-K report.
